Communiqués Prothena Corporation plc

Actions

PRTA

IE00B91XRN20

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/08/2026			Varia. 5j.	Varia. 1 janv.
9,120 ^USD	+4,11%		+9,48%	-4,50%

06/08	Prothena Corporation plc publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
05/06	Prothena Corp Public Ltd : un initié acquiert des actions pour un montant de 465 295 $, selon une déclaration à la SEC	MT

Communiqués

06/08	Prothena: Q2 Earnings Snapshot	AQ
06/08	Prothena Reports Second Quarter 2026 Financial Results and Business Highlights	BU
30/07	Prothena to Report Second Quarter 2026 Financial Results on August 6	BU
08/05	Prothena : Corporate Overview	PU
08/05	Prothena : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Prothena: Q1 Earnings Snapshot	AQ
07/05	Prothena Reports First Quarter 2026 Financial Results and Business Highlights	BU
30/04	Prothena to Report First Quarter 2026 Financial Results on May 7	BU
27/04	Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy	BU
10/04	Prothena Announces Leadership Team Updates	BU
27/03	Prothena : Director's Report and Financial Statements for Fiscal Year 2025	PU
21/03	Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026	BU
09/03	Prothena : Corporate Overview	PU
09/03	Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy	BU
02/03	Prothena Announces up to $100 Million Share Repurchase Plan	AQ
27/02	Prothena Announces up to $100 Million Share Repurchase Plan	BU
19/02	Prothena: Q4 Earnings Snapshot	AQ
19/02	Prothena : Earnings Presentation	PU
19/02	Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights	BU
12/02	Prothena to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026	BU
12/01	Prothena : Corporate Overview	PU
12/12	Prothena Announces Board of Directors Update	BU
01/12	Prothena : Corporate Overview	PU
19/11	Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025	BU
12/11	Prothena Highlights Phase 2 Data for Coramitug Published in Circulation, Official Journal of AHA	AQ